Risk of selecting K65R in anti retroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir
ABSTRACT Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not require antiretroviral therapy.
- SourceAvailable from: yynet.cn
[Show abstract] [Hide abstract]
- "Caution is warranted, however, because adefovir may possess some degree of anti-HIV activity. In the late 1990s, adefovir was investigated as an anti- HIV agent at doses of 60 to 120 mg, but at the 10 mg dose it neither has activity against HIV nor selects for the K65R HIV-resistance mutation . "
ABSTRACT: The approach to the hepatitis B virus (HBV)-infected patient who is also infected with HIV or hepatitis C virus (HCV) is very different from the approach to the patient with only one virus infection. HBV/HIV coinfection is common. Agents that have dual activity against HBV and HIV should be considered as treatment of choice in combination regimens in HBV/HIV-coinfected patients beginning antiretroviral therapy. In HBV/HCV coinfection HCV usually tends to predominate over HBV. More investigation is needed into the mechanisms by which viral pathogenesis is altered and the optimal treatment modalities for coinfected patients.Clinics in Liver Disease 12/2007; 11(4):917-43, ix-x. DOI:10.1016/j.cld.2007.08.007 · 2.70 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Chronic Hepatitis B, were considered in the development of these guidelines.3-7 The recommendations suggest pre- ferred approaches to the diagnostic, therapeutic, and pre- ventive aspects of care. They are intended to be flexible. Specific recommendations are based on relevant pub- lished information. In an attempt to characterize the qual- ity of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a category to be assigned and reported with each recommendation (Table 1). These guidelines may be updated periodically as new information becomes available.